
Grail plans FDA filing for cancer blood test after new trial
Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.
Newsletters and Deep Dive digital magazine
Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.
The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as the agency's leadership in this area is sidelined.
The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference
MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Editor's Picks
Newsletters and Deep Dive
digital magazine